OPB-31121

DRUG4 trials

Sponsors

Otsuka Beijing Research Institute, Korea Otsuka Pharmaceutical Co., Ltd., M.D. Anderson Cancer Center, Otsuka Pharmaceutical Co., Ltd.

Conditions

Advanced CancerHepatocellular CarcinomaMultiple MyelomaNon-Hodgkin's Lymphoma(NHL)Solid Tumor

Phase 1

Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

CompletedNCT00511082

Otsuka Beijing Research InstituteMultiple Myeloma, Non-Hodgkin's Lymphoma(NHL)

Start: 2007-12-31End: 2010-07-31Updated: 2025-04-16

An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors

Korea Otsuka Pharmaceutical Co., Ltd.Solid Tumor

Start: 2008-03-31End: 2009-06-30Target: 36Updated: 2008-04-18

STAT3 Inhibitor for Solid Tumors

CompletedNCT00955812

M.D. Anderson Cancer CenterAdvanced Cancer, Solid Tumor

Start: 2009-06-30End: 2012-11-30Updated: 2013-02-12

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

CompletedNCT01406574

Otsuka Pharmaceutical Co., Ltd.Hepatocellular Carcinoma

Start: 2011-07-31End: 2014-03-31Updated: 2015-06-08

Related Papers

A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2014-05-201 citations